Discrimination of white matter lesions and multiple sclerosis plaques by short echo quantitative 1H-magnetic resonance spectroscopy

Journal of Neurology

Volumn 252, Issue 10, 2005, Pages 1229-1234

  Kapeller, P ^a,b   Ropele, S ^a   Enzinger, C ^a   Lahousen, T ^a   Strasser Fuchs, S ^a   Schmidt, R ^a   Fazekas, F ^a  

^a UNIVERSITY OF GRAZ   (Austria)

^b NONE   (Austria)

Author keywords

Magnetic resonance spectroscopy; Multiple sclerosis; White matter lesions

Indexed keywords

INOSITOL; N ACETYLASPARTIC ACID;

ADULT; AGED; ARTICLE; BRAIN INJURY; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; FEMALE; HUMAN; MALE; METABOLITE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; QUANTITATIVE DIAGNOSIS; WHITE MATTER;

ADULT; AGED; ANALYSIS OF VARIANCE; ASPARTIC ACID; BRAIN; CASE-CONTROL STUDIES; CREATINE; FEMALE; FOURIER ANALYSIS; HUMANS; INOSITOL; LACTIC ACID; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MULTIPLE SCLEROSIS; PHOSPHOCREATINE;

EID: 26844447524     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-005-0847-3     Document Type: Article

References (35)

1. Lassmann H (1998) Neuropathology in multiple sclerosis: new concepts. Mult Scler 4:93-98
2. Fazekas F, Kleinert R, Offenbacher H, Schmidt R, Kleinert G, Payer F, Radner H, Lechner H (1993) Pathologic correlates of incidental MRI white matter signal hyperintensities. Neurology 43:1683-1689
3. Fazekas F, Offenbacher H, Fuchs S, Schmidt R, Niederkorn K, Horner S, Lechner H (1988) Criteria for an increased specificity of MRI interpretation in elderly subjects with suspected multiple sclerosis. Neurology 38:1822-1825
4. Barkhof F, Filippi M, Miller D, Scheltens P, Campi A, Polman C, Comi G, Ader H, Losseff N, Valk J (1997) Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 120:2059-2069
5. Paty DW, Kastrukoff LF, Hashimoto SA, Hooge JP, Eisen AA, Eisen KA, Purves SJ, Low MD, Brandejs V (1988) MRI in the diagnosis of MS: a prospective study with comparison of clinical evaluation, evoked potentials, oligoclonal banding, and CT. Neurology 38:180-185
6. Offenbacher H, Fazekas F, Schmidt R, Freidl W, Flooh E, Payer F, Lechner A (1993) Assessment of MRI criteria for a diagnosis of MS. Neurology 43:905-909
7. Bitsch A, Bruhn H, Vougioukas V, Stringaris A, Lassmann H, Frahm J, Brück W (1999) Inflammatory CNS demyelination: histopathologic correlation with in vivo quantitative proton MR spectroscopy. AJNR 20:1619-1627
8. Fazekas F, Kleinert R, Offenbacher H (1991) The morphologic correlate of incidental punctate white matter hyperintensities on MR images. AJNR Am J Neuroradiol 12:915-921
9. Scheltens P, Barkhof F, Leys D, Wolters E, Ravid R, Kamphorst W (1995) Histopathologic correlates of white matter changes on MRI in Alzheimer's disease and normal aging. Neurol 45:883-888
10. 1H magnetic resonance spectroscopy of chronic cerebral white matter lesions and normal appearing white matter in multiple sclerosis. J Neurol Neurosurg Psychiatry 63:736-742
11. Van Walderveen M, Kamphorst W, Scheltens P, van Waesberghe J, Ravid R, Valk J, Polman C, Barkhof F (1998) Histopathologic correlate of hypointense lesions of T1-weighted spinecho MRI in multiple sclerosis. Neurology 50:1282-1288
12. Brex P, Gomez-Anson B, Parker G, Molyneux P, Miszkiel K, Barker G, MacManus D, Davie C, Plant G, DH M (1999) Proton MR spectroscopy in clinically isolated syndromes suggestive of multiple sclerosis. J Neurol Sci 166:16-22
13. Brex P, Parker G, Leary S, Molyneux P, Barker G, Davie C, Thompson A, Miller D (2000) Lesion heterogeneity in multiple sclerosis: a study of the relations between appearances on T1 weighted images, T1 relaxation times, and metabolite concentrations. J Neurol Neurosurg Psychiatry 68:627-632
14. Kapeller P, McLean M, Griffin C, Chard D, Parker G, Barker G, Thompson A, Miller D (2001) Evidence for neuronal damage in cortical grey matter and normal appearing white matter in early relapsing remitting multiple sclerosis: a quantitative MR spectroscopic imaging study. J Neurol 248:131-138
15. 1H MRS imaging 14 years after presenting with a clinically isolated syndrome suggestive of multiple sclerosis. Mult Scler 8:207-210
16. Miller B, Moats R, Shonk T, Ernst T, Wooley S, Ross B (1993) Alzheimer disease: depiction of increased cerebral myo-inositol with proton MR Spectrosc. Radiol 187:433-437
17. Behar K, Boucher R, Fritch W, Manuelidis L (1998) Changes in N-acetyl-aspartate and myo-inositol detected in the cerebral cortex of hamsters with Creutzfeld-Jakob disease. MRI 16:963-968
18. Thurston J, Sherman W, Hauhart R, Kloepper R (1989) myo-inositol: a newly identified nonnitrogenous osmoregulatory molecule in mammalian brain. Pediatr Res 26:482-485
19. Chard D, Griffin C, McLean M, Kapeller P, Kapoor R, Thompson A, Miller D (2002) Brain metabolite changes in cortical grey and normal-appearing white matter in clinically early relapsing-remitting multiple sclerosis. Brain 125:2342-2352
20. Oppenheimer S, Bryan R, Conturo T, Soher B, Preziosi T, Barker P (1995) Proton magnetic resonance spectroscopy and gadolinium-DTPA perfusion imaging of asymptomatic MRI white matter lesions. Magn Reson Med 33:61-68
21. Provencher S (1993) Estimation of metabolite concentrations from localised in vivo proton NMR spectra. MRM 30:672-679
22. Brand A, Richter-Landsberg C, Leibfritz D (1993) Multinuclear NMR studies on the energy metabolism of glial and neuronal cells. Dev Neurosci 15:289-298
23. Simmons M, Frondoza C, Coyle J (1991) Immunocytochemical localisation of N-acetyl-aspartate with monoclonal antibodies. Neuroscience 45:37-45
24. Narayana P, Doyle T, Lai D, Wolinsky J (1998) Serial proton magnetic resonance spectroscopic imaging, contrast enhanced magnetic resonance imaging, and quantitative lesion volumetry in multiple sclerosis. Ann Neurol 43:56-71
25. Gonen O, Catalaa I, Babb J, Ge Y, Mannon L, Kolson D, Grossman R (2000) Total brain N-acetylaspartate: a new measure of disease load in MS. Neurology Jan 11:15-19
26. Van Waesberghe J, Kamphorst W, de Groot C, van Walderveen M, Castelijns J, Ravid R, Lycklama a Nijeholt G, van der Valk P, Polman C, Thompson A, Barkhof F (1999) Axonal loss in multiple sclerosis lesions: magnetic resonance imaging insights into substrates of disability. Ann Neurol 46:747-754
27. Buniatian HC, Hovhannissian VS, Aprikian GV (1965) The Participation of N-Acetyl-l-Aspartic acid in Brain Metabolism. J Neurochem 12:695-703
28. Awad I, Spetzler R, Hodak J, Awad C, Carey R (1986) Incidental subcortical lesions identified on magnetic resonance imaging in the elderly. I. Correlation with age and cerebrovascular risk factors. Stroke 17:1084-1089
29. Schmidt R, Fazekas F, Hayn M, Schmidt H, Kapeller P, Roob G, Offenbacher H, Schumacher M, Eber B, Weinrauch V, Kostner G, Esterbauer H (1997) Risk factors for microangiopathy-related cerebral damage in the Austrian stroke prevention study. J Neurol Sci 152:15-21
30. Schmidt R, Fazekas F, Offenbacher H, Kapeller P, Schmidt H, Roob G (1998) Prevalence and risk factors for white matter damage. In: Fazekas F, Schmidt R, Alavi A (eds) Neuroimaging of normal ageing and uncommon causes of dementia. Dordrecht: ICG Publications, pp 11-25
31. Kapeller P, Fazekas F, Schmidt R (2002) Vascular white matter changes. In: Leys D (ed) Stroke: Predisposing Conditions. London: Remedica, pp 89-97
32. Fazekas F (1989) Magnetic resonance signal abnormalities in asymptomatic individuals: their incidence and functional correlates. Eur Neurol 29:164-168
33. Mader I, Roser W, Kappos L, Hagberg G, Seelig J, Radue E, Steinbrich W (2000) Serial Proton MR Spectroscopy of Contrast-enhancing Multiple Sclerosis Plaques: Absolute Metabolic Values over 2 Years during a Clinical Pharmacological Study. AJNR 21:1220-1227
34. Inglese M, Li B, Rusinek H, Babb J, Grossman R, Gonen O (2003) Diffusely elevated cerebral choline and creatine in relapsing-remitting multiple sclerosis. Magn Reson Med 50:190-195
35. 1H MR spectroscopy. Ann Neurol 46:79-87